Savara (SVRA) Return on Capital Employed (2011 - 2026)
Savara (SVRA) posted quarterly Return on Capital Employed of 60.41% for Q1 2026, down 271.0% year-over-year from 35.33% in Q1 2025, and up 13.57% quarter-over-quarter from 69.89% in Q4 2025.
Savara (SVRA) Return on Capital Employed (2011 - 2026) Analysis & Trends
Savara (SVRA) has reported Return on Capital Employed for 16 consecutive years, with 60.41% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 271.0% year-over-year to 60.41%; the TTM figure through Mar 2026 stood at 60.41% (down 271.0% YoY), while the FY2025 annual figure was 58.07%, down 90.0% from the prior year.
- Return on Capital Employed rose to 60.41% in Q1 2026 per SVRA's latest filing, from 69.89% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.11% in Q2 2022 and bottomed at 89.47% in Q3 2025.
- Historically, Return on Capital Employed has averaged 47.12% across 5 years, with a median of 44.5% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 467 bps — and 2025, when it tumbled 3866 bps.
- Savara's Return on Capital Employed stood at 28.16% in 2022, then retreated by 26 bps to 35.46% in 2023, then plunged by 38 bps to 48.88% in 2024, then tumbled by 43 bps to 69.89% in 2025, then gained by 14 bps to 60.41% in 2026.
- Business Quant data shows SVRA's Return on Capital Employed at 60.41% in Q1 2026, 69.89% in Q4 2025, and 89.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -75.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -75.88% |
| Mar 31, 2026 | -60.41% |
| Dec 31, 2025 | -69.89% |
| Sep 30, 2025 | -89.47% |
| Jun 30, 2025 | -72.07% |
| Mar 31, 2025 | -57.69% |
| Dec 31, 2024 | -48.88% |
| Sep 30, 2024 | -50.81% |
| Jun 30, 2024 | -59.07% |
| Mar 31, 2024 | -44.50% |
| Dec 31, 2023 | -35.46% |
| Sep 30, 2023 | -37.50% |
| Jun 30, 2023 | -38.53% |
| Mar 31, 2023 | -33.09% |
| Dec 31, 2022 | -28.16% |
| Sep 30, 2022 | -26.24% |
| Jun 30, 2022 | -24.11% |
| Mar 31, 2022 | -25.22% |
| Dec 31, 2021 | -24.80% |
| Sep 30, 2021 | -24.20% |